Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a pediatric referral hospital in Uruguay

Pediatric Infectious Disease Journal

Volumn 33, Issue 7, 2014, Pages 753-759

  Pírez, María Catalina ^a   Algorta, Gabriela ^a   Chamorro, Flavia ^a   Romero, Claudia ^a   Varela, Adriana ^b   Cedres, Alejandra ^a   Giachetto, Gustavo ^a   Montano, Alicia ^a  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^b INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

Author keywords

Haemophilus influenzae; pneumonia; Staphylococcus aureus; Streptococcus pneumoniae; vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; HAEMOPHILUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ADOLESCENT; ARTICLE; CHILD; COMMUNITY ACQUIRED INFECTION; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFANT; NEWBORN; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; SEROTYPE; STAPHYLOCOCCUS AUREUS; URUGUAY; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; MALE; PNEUMONIA, BACTERIAL; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; TRENDS; UTILIZATION; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HAEMOPHILUS VACCINES; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; URUGUAY; VACCINATION;

EID: 84902551152     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000294     Document Type: Article

References (40)

1. Challenges in global immunization and the Global Immunization Vision and Strategy 2006-2015. Wkly Epidemiol Rec. 2006;19:190-195.
2. Pneumococcal conjugate vaccine. WHO position paper. Wkly Epidemiol Rec. 2012;87:129-144.
3. Pneumonia: the forgotten killer of children, 2006. Geneva: UNICEF/WHO 2006. Available at: www.unicef.org. Accessed October 7, 2013.
4. Madhi SA, Levine OS, Hajjeh R, et al. Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ. 2008;86:365-372.
5. Torres C, Mujica OJ. [Health, equity, and the Millennium Development Goals]. Rev Panam Salud Publica. 2004;15:430-439.
6. Ferrari AM, Pirez MC, Martinez A, et al. Etiologia de la neumonia bacteriana adquirida en la comunidad en ninos hospitalizados. Uruguay 1998-2004. Rev Chil Infect. 2007; 24:45-52.
7. Hortal M, Sehabiague G, Camou T, et al. Pneumococcal pneumonia in hospitalized Uruguayan children and potential prevention with different vaccine formulations. J Pediatr. 2008;152:850-853.
8. Montano A, Algorta G, Pirez MC, et al. Enfermedades invasivas por Haemophilus Influenzae tipo b. Impacto de la vacunacion en los ninos que ingresan al Centro Hospitalario Pereira Rossell. Rev Med Uruguay. 2001;17:166-170.
9. Landaverde M, Di Fabio JL, Ruocco G, et al. [Introduction of a conjugate vaccine against Hib in Chile and Uruguay]. Rev Panam Salud Publica. 1999;5:200-206.
10. Programa nacional operativo de inmunizaciones. [Comision horaria de la lucha antituberculosas y enfermedades prevalentes. web site]. March 18, 2013. Available at: http://www.chlaep.org.uy/programas-inmunizacionesestadisticas. php. Accessed December 6, 2013.
11. Amorin MB, Castro M, Sandin D, et al. Infecciones invasivas por Staphylococcus aureus meticilino resistente adquirido en la comunidad. Presentacion clinica y evolutiva observada en dos centros universitarios. Uruguay 2003-2007. Rev Med Urug. 2008;24:230-237.
12. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
13. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:e00309-e00310.
14. Patrza?ek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis. 2010;29:787-792.
15. Elemraid MA, Rushton SP, Shirley MD, et al.; North East of England Paediatric Respiratory Infection Study Group. Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia. Epidemiol Infect. 2013;141:1697-1704.
16. Pirez MC, Algorta G, Cedres A, et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J. 2011;30:669-674.
17. Hortal M, Estevan M, Laurani H, et al.; Paysandu/Salto Study Group. Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine. 2012;30:4934-4938.
18. Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics. 2004;113:1735-1740.
19. Versalovic J, Carroll KC, Funke G, et al. Manual of Clinical Microbiology. 10th ed. Washington, DC: American Society for Microbiology; 2011.
20. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-second Informational Supplement, CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
21. Pirez MC, Montano A, Rubio I, et al. Normas nacionales de diagnástico, tratamiento y prevencián. 7ma edicion. Montevideo: Oficina del Libro FEFMUR; 2008.
22. O'Brien KL, Wolfson LJ, Watt JP, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
23. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25:409-419.
24. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis. 2008;46:1346-1352.
25. Pirez MC, Martinez O, Ferrari AM, et al. Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998. Pediatr Infect Dis J. 2001;20:283-289.
26. Machado K, Kouyoumdjian G, Algorta MC, et al. Neumonia necrotizante en ninos hospitalizados en el Hospital Pediatrico-Centro Hospitalario Pereira Rossell en el ano 2010. Arch Pediatr Urug. 2013;84:101-110.
27. Lagos R, Munoz A, San Martin O, et al. Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994-2007. J Infect Dis. 2008;198:1809-1817.
28. Gabastou JM, Agudelo CI, Brandileone MC, et al.; Grupo de Laboratorio de SIREVA II. [Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000-2005]. Rev Panam Salud Publica. 2008;24:1-15.
29. Ruvinsky R, Regueira M, Fossati MS, et al. Surveillance of invasive in Streptococcus pneumoniae in Argentina 1994-2007: changes in serotype distribution, serotype coverage of pneumococcal conjugate vaccines and antibiotic resistance, J Pediatr Infect Dis. 2010;5:263-269.
30. Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369: 155-163.
31. Bryant KA, Block SL, Baker SA, et al.; PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125:866-875.
32. Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013;310:930-937.
33. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32:203-207.
34. Health Protection Agency, Centre for Infections. Available at: www. hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/ EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/InPrevenar13 Not In PrevenarPCV7/. Accessed October 4, 2013.
35. Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952-962.
36. Dagan R, Gradstein S, Belmaker I, et al. An outbreak of Streptococcus pneumoniae serotype 1 in a closed community in southern Israel. Clin Infect Dis. 2000;30:319-321.
37. Romney MG, Hull MW, Gustafson R, et al. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clin Infect Dis. 2008;47:768-774.
38. Mothibeli KM, du Plessis M, von Gottberg A, et al.; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). An unusual pneumococcal sequence type is the predominant cause of serotype 3 invasive disease in South Africa. J Clin Microbiol. 2010;48:184-191.
39. Benoit SR, Estivariz C, Mogdasy C, et al. Community strains of methicillin- resistant Staphylococcus aureus as potential cause of healthcare- associated infections, Uruguay, 2002-2004. Emerg Infect Dis. 2008;14:1216-1223.
40. Pardo L, Vola M, Macedo-Vinas M, et al. Community-associated methicillin- resistant Staphylococcus aureus in children treated in Uruguay. J Infect Dev Ctries. 2013;7:10-16.